SMARTER TOGETHER’s overarching vision is to find the right balance between smart technologies and organizational/ governance dimensions in order to deliver smart and inclusive solutions and to improve citizen’s quality of life. SMARTER TOGETHER gather the European Lighthouse cities Lyon, Munich, Vienna, the Follower cities Santiago de Compostela, Sofia, Venice and Kyiv and Yokohama as observer cities bringing the perspective of East Europe and Asia. The cities are complemented by business partners from energy, mobility and ICT sectors, leading European research and academia organizations, european city network. From the various combinations of the different selected Light House areas, multiples opportunities to learn are offering. SMARTER TOGETHER delivers 5 clusters of co-created, smart and integrated solutions: (1) Living labs for citizen engagement, (2) District heating and RES for low energy districts, (3) Holistic refurbishment for low energy districts addressing public and private housing, (4) Smart Data management platform and smart services (5) E-mobility solutions for sustainable mobility. Expected results are: 1) >151,800 m2 of refurbished buildings, primarily housing estate with a 50-60 % average energy and CO2 reduction; 2) 14.6 MW of newly installed renewable capacity; 3) 10/15new e-mobility solutions for passengers and freight); 4) 1400 created jobs, 130 M€ investments, all deployed with support of integrated ICT solutions and in dialogue with the inhabitants. Large-scale replication will be prepared; 1) in the Lighthouse cities; 2) the Follower cities, which already selected their target area; 3) A Club of 15-20 cities, associate to intensify its roll-out, ensuring a broad geographical and climate coverage. Commercial exploitation is enhanced by the development of new business models for widespread use by the stakeholders. Contributions to open data are expected to create business opportunities as well as inputs to standardization work.

Beyond the role the intestinal metagenome plays in regulating multiple physBeyond its role in regulating multiple physiological functions that impact health, the intestinal metagenome is implicated in cancer initiation, progression and responses to therapies, even for extraintestinal neoplasia. Hence, there is an urgent need to fully identify and functionally characterize minimalist commensal ecosystems relevant to cancer, with reliable and robust methods, to validate cancer-associated gut microbiome fingerprints of high clinical relevance, and to develop diagnosis tools that will become part of the oncological arsenal for the optimization and personalization of therapy. Based on retro-and pro-spective studies, with large discovery and validation cohorts enrolling >9,000 cancer patients across 10 countries, ancillary to ongoing innovative clinical trials or FDA/EMA approvals across 4 frequent cancer types, ONCOBIOME will pursue the following aims: 1/ identify and validate core or cancer-specific Gut OncoMicrobiome Signatures (GOMS) associated with cancer occurrence, prognosis, response to, or progression on, therapy (polychemotherapy, immune checkpoint inhibitors, dendritic cell vaccines) or adverse effects, 2/ decipher the functional relevance of these cancer-associated gut commensal ecosystems in the regulation of host metabolism, immunity and oncogenesis, 3/ integrate these GOMS with other oncology hallmarks (clinics, genomics, immunomics, metabolomics) 4/ design optimal companion tests, based on those integrated signatures to predict cancer occurrence and progression. With high carat interdisciplinary experts, ONCOBIOME expects to validate cancer or therapy-specific Gut OncoMicrobiome Signatures (GOMS) across breast, colorectal, melanoma and lung cancers adjusting for covariates, to unravel the mode of action of these GOMS in innovative platforms, thus lending support to the design of cancer preventive campaigns using well characterized pre-and pro-biotics.